Nuformix PLC Change of Auditor (0956D)
March 01 2022 - 1:01AM
UK Regulatory
TIDMNFX
RNS Number : 0956D
Nuformix PLC
01 March 2022
1 March 2022
Nuformix plc
("Nuformix" or the "Company")
Change of Auditor
Nuformix plc (LSE: NFX), a pharmaceutical development company
targeting unmet medical needs in fibrosis and oncology via drug
repurposing, is pleased to announce the appointment of Jeffreys
Henry LLP ("Jeffreys Henry") as auditor to the Company. The
appointment of Jeffreys Henry will be subject to approval by
shareholders at the next Annual General Meeting of the Company.
The appointment of Jeffreys Henry follows the resignation of
Haysmacintyre LLP who has confirmed to the Company that there are
no circumstances connected with its resignation which it considers
should be brought to the attention of the members or creditors of
the Company. As required by the Companies Act, Nuformix will send a
copy of the resignation letter to shareholders.
Enquiries:
Nuformix plc
Dr Alastair Riddell, Executive Chairman Via IFC Advisory
Stanford Capital Partners Limited
Tom Price / Patrick Claridge (Corporate
Finance) +44 (0) 20 3650 3650
John Howes (Corporate Broking) +44 (0) 20 3650 3652
IFC Advisory Limited
Tim Metcalfe +44 (0) 20 3934 6630
Zach Cohen nuformix@investor-focus.co.uk
About Nuformix
Nuformix is a pharmaceutical development company targeting unmet
medical needs in fibrosis and oncology via drug repurposing. The
Company aims to use its expertise in discovering, developing and
patenting novel drug forms, with improved physical properties, to
develop new products in new indications that are, importantly,
differentiated from the original (by way of dosage, delivery route
or presentation), thus creating new and attractive commercial
opportunities. Nuformix has an early-stage pipeline of preclinical
and Phase I-ready assets with potential for significant value and
early licensing opportunities.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
APPEAXAPAALAEFA
(END) Dow Jones Newswires
March 01, 2022 02:01 ET (07:01 GMT)
Nuformix (LSE:NFX)
Historical Stock Chart
From Jun 2024 to Jul 2024
Nuformix (LSE:NFX)
Historical Stock Chart
From Jul 2023 to Jul 2024